Ivosidenib is a potent, reversible and selective inhibitor of mutated Isocitrate Dehydrogenase 1 (IDH1). Ivosidenib binds and inhibits the mutant IDH1 enzyme that is responsible for the accumulation of 2-Hydroxyglutarate (2-HG).
6 Therapies|Clear filters
Reg. name: Tibsovo
Class: IDH1 inhibitor
TIBSOVO® is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
Reg. name: Rydapt®
Class: Multi-targeted Tyrosine Kinase Inhibitor (TKI)
RYDAPT® is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation positive, as detected by a FDA approved test.